PepGen Inc. (PEPG)
PepGen Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $2.90, down 3.01% on the session, giving a market capitalisation of $200.6M. On trailing twelve-month figures it carries a trailing P/E of -1.93, a net margin of 0.0%. Its beta of 1.89 implies it has historically moved more than the broad market.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
PepGen Inc. is most often compared with the following Healthcare names: